<ul>
<li>核能、製藥與旅遊回購：信心還是謹慎的信號？</li>
</ul>
<p>根據 MarketBeat 的股票篩選工具，禮來公司、雅培和艾伯維是今天值得關注的三隻製藥股票。製藥股票是指那些研究、開發、生產和銷售處方藥、疫苗及其他治療產品的上市公司股票。它們包括大型綜合製藥公司以及專注於特定療法的小型生物技術公司。對於投資者而言，這些股票通常受到臨牀試驗結果、監管批准、專利到期和定價/政策變化的驅動，創造出二元的上行潛力以及較高的波動性和風險。這些公司在過去幾天內的交易量是所有制藥股票中最高的。</p>
<p>獲取 <strong>禮來公司</strong> 的提醒：</p>
<h2>禮來公司 (LLY)</h2>
<p>禮來公司在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素利普羅、胰島素利普羅原料、胰島素利普羅混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；Zepbound 用於肥胖。</p>
<ul>
<li>禮來的下一個帝國：對人工智能和神經科學的 100 億美元投資</li>
</ul>
<p>閲讀我們關於 LLY 的最新研究報告</p>
<h2>雅培 (ABT)</h2>
<p>雅培公司及其子公司在全球範圍內發現、開發、生產和銷售醫療保健產品。它分為四個部門：成熟藥品、診斷產品、營養產品和醫療器械。該公司提供用於治療胰腺外分泌功能不全、腸易激綜合症或膽道痙攣、肝內膽汁淤積或抑鬱症、婦科疾病、激素替代療法、血脂異常、高血壓、甲狀腺功能減退、梅尼埃病和前庭性眩暈、疼痛、發熱、炎症和偏頭痛的仿製藥，以及提供抗感染藥物克拉黴素、流感疫苗和調節結腸生理節律的產品。</p>
<ul>
<li>默克剛剛在一個新的癌症增長引擎上進行了重大投資</li>
</ul>
<p>閲讀我們關於 ABT 的最新研究報告</p>
<h2>艾伯維 (ABBV)</h2>
<p>艾伯維公司在全球範圍內發現、開發、生產和銷售藥品。該公司提供 Humira，一種用於自身免疫性和腸道貝赫切特病及膿皮病的注射藥物；Skyrizi 用於治療中度至重度斑塊型銀屑病、銀屑病性疾病和克羅恩病；Rinvoq 用於治療類風濕性關節炎和銀屑病性關節炎、強直性脊柱炎、特應性皮炎、軸性脊柱關節病、潰瘍性結腸炎和克羅恩病；Imbruvica 用於治療成人血癌；Epkinly 用於治療淋巴瘤；Elahere 用於治療癌症；Venclexta/Venclyxto 用於治療血癌。</p>
<p>閲讀我們關於 ABBV 的最新研究報告</p>
<h2>推薦故事</h2>
<ul>
<li>MarketBeat 2026 年 4 月值得擁有的五大股票</li>
<li>隨着耐克股票接近 12 年低點，現在是勇敢出手的時候嗎？</li>
<li>三家不同的金融科技巨頭：轉型、穩定還是冒險投資？</li>
<li>微軟的 Copilot 問題並不是你想的那樣</li>
<li>2026 年三隻令人驚訝的標普 500 超越者</li>
<li>羅素 2000 追蹤新高：ETF 交易者接下來會怎樣？</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在禮來公司嗎？</h2>
<p>在你考慮禮來公司之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前……而禮來公司並不在名單上。</p>
<p>雖然禮來公司目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

醫療業 ETF - Vanguard

基因改革 ETF - ARK

醫療業 ETF - SPDR

<p>根據 MarketBeat 的報道，禮來、雅培和艾伯維被認為是值得關注的頂級製藥股票。這些公司涉及開發和銷售各種醫療產品，包括糖尿病藥物和自身免疫疾病的治療。它們的股票受到臨牀試驗、監管變化和市場動態的影響，因此既是有前景的投資，也具有波動性。儘管禮來獲得了適度買入評級，但分析師建議其他股票可能提供更好的投資機會</p>

<ul>
<li>Nuclear, Pharma &amp; Travel Buybacks: Confident or Cautious Signals?</li>
</ul>
<div class="lb-trans"><ul>
<li>核能、製藥與旅遊回購：信心還是謹慎的信號？</li>
</ul>
</div><p>Eli Lilly and Company, Abbott Laboratories, and AbbVie are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription drugs, vaccines, and other therapeutic products. They include large integrated drugmakers as well as smaller biotechnology firms focused on specific therapies. For investors these stocks are often driven by clinical trial results, regulatory approvals, patent expirations and pricing/policy changes, creating both binary upside potential and elevated volatility and risk. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p>
<div class="lb-trans"><p>根據 MarketBeat 的股票篩選工具，禮來公司、雅培和艾伯維是今天值得關注的三隻製藥股票。製藥股票是指那些研究、開發、生產和銷售處方藥、疫苗及其他治療產品的上市公司股票。它們包括大型綜合製藥公司以及專注於特定療法的小型生物技術公司。對於投資者而言，這些股票通常受到臨牀試驗結果、監管批准、專利到期和定價/政策變化的驅動，創造出二元的上行潛力以及較高的波動性和風險。這些公司在過去幾天內的交易量是所有制藥股票中最高的。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>禮來公司</strong> 的提醒：</p>
</div><h2>Eli Lilly and Company (LLY)</h2>
<div class="lb-trans"><h2>禮來公司 (LLY)</h2>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>禮來公司在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素利普羅、胰島素利普羅原料、胰島素利普羅混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；Zepbound 用於肥胖。</p>
</div><ul>
<li>Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience</li>
</ul>
<div class="lb-trans"><ul>
<li>禮來的下一個帝國：對人工智能和神經科學的 100 億美元投資</li>
</ul>
</div><p>Read Our Latest Research Report on LLY</p>
<div class="lb-trans"><p>閲讀我們關於 LLY 的最新研究報告</p>
</div><h2>Abbott Laboratories (ABT)</h2>
<div class="lb-trans"><h2>雅培 (ABT)</h2>
</div><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p>
<div class="lb-trans"><p>雅培公司及其子公司在全球範圍內發現、開發、生產和銷售醫療保健產品。它分為四個部門：成熟藥品、診斷產品、營養產品和醫療器械。該公司提供用於治療胰腺外分泌功能不全、腸易激綜合症或膽道痙攣、肝內膽汁淤積或抑鬱症、婦科疾病、激素替代療法、血脂異常、高血壓、甲狀腺功能減退、梅尼埃病和前庭性眩暈、疼痛、發熱、炎症和偏頭痛的仿製藥，以及提供抗感染藥物克拉黴素、流感疫苗和調節結腸生理節律的產品。</p>
</div><ul>
<li>Merck Just Made a Big Bet on a New Cancer Growth Engine</li>
</ul>
<div class="lb-trans"><ul>
<li>默克剛剛在一個新的癌症增長引擎上進行了重大投資</li>
</ul>
</div><p>Read Our Latest Research Report on ABT</p>
<div class="lb-trans"><p>閲讀我們關於 ABT 的最新研究報告</p>
</div><h2>AbbVie (ABBV)</h2>
<div class="lb-trans"><h2>艾伯維 (ABBV)</h2>
</div><p>AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯維公司在全球範圍內發現、開發、生產和銷售藥品。該公司提供 Humira，一種用於自身免疫性和腸道貝赫切特病及膿皮病的注射藥物；Skyrizi 用於治療中度至重度斑塊型銀屑病、銀屑病性疾病和克羅恩病；Rinvoq 用於治療類風濕性關節炎和銀屑病性關節炎、強直性脊柱炎、特應性皮炎、軸性脊柱關節病、潰瘍性結腸炎和克羅恩病；Imbruvica 用於治療成人血癌；Epkinly 用於治療淋巴瘤；Elahere 用於治療癌症；Venclexta/Venclyxto 用於治療血癌。</p>
</div><p>Read Our Latest Research Report on ABBV</p>
<div class="lb-trans"><p>閲讀我們關於 ABBV 的最新研究報告</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>MarketBeat's Top Five Stocks to Own in April 2026</li>
<li>With Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?</li>
<li>3 Different Fintech Giants: Turnaround, Stability, or Risky Bet?</li>
<li>Microsoft’s Copilot Problem Isn’t What You Think</li>
<li>3 Surprising S&amp;P 500 Outperformers of 2026</li>
<li>Russell 2000 Tracking for New Highs: What’s Next for ETF Traders?</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 2026 年 4 月值得擁有的五大股票</li>
<li>隨着耐克股票接近 12 年低點，現在是勇敢出手的時候嗎？</li>
<li>三家不同的金融科技巨頭：轉型、穩定還是冒險投資？</li>
<li>微軟的 Copilot 問題並不是你想的那樣</li>
<li>2026 年三隻令人驚訝的標普 500 超越者</li>
<li>羅素 2000 追蹤新高：ETF 交易者接下來會怎樣？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在禮來公司嗎？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮禮來公司之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前……而禮來公司並不在名單上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然禮來公司目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

4 月 12 日值得關注的最佳製藥股票